1236 related articles for article (PubMed ID: 28825375)
41. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
42. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
43. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Hull RD; Pineo GF; Brant RF; Mah AF; Burke N; Dear R; Wong T; Cook R; Solymoss S; Poon MC; Raskob G;
Am J Med; 2007 Jan; 120(1):72-82. PubMed ID: 17208082
[TBL] [Abstract][Full Text] [Related]
44. Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care.
Bouillon K; Bertrand M; Boudali L; Ducimetière P; Dray-Spira R; Zureik M
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27799233
[TBL] [Abstract][Full Text] [Related]
45. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
46. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
47. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
48. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
49. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
[TBL] [Abstract][Full Text] [Related]
50. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
51. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
52. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Bacchus F; Schulman S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):513-9. PubMed ID: 25717178
[TBL] [Abstract][Full Text] [Related]
53. Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer.
Soff GA
J Natl Compr Canc Netw; 2018 May; 16(5S):670-673. PubMed ID: 29784753
[TBL] [Abstract][Full Text] [Related]
54. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
55. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
56. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Levine MN; Raskob G; Beyth RJ; Kearon C; Schulman S
Chest; 2004 Sep; 126(3 Suppl):287S-310S. PubMed ID: 15383476
[TBL] [Abstract][Full Text] [Related]
57. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
58. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
[TBL] [Abstract][Full Text] [Related]
59. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants.
Park CS; Choi EK; Kim HM; Lee SR; Cha MJ; Oh S
Heart Rhythm; 2017 Apr; 14(4):501-507. PubMed ID: 28042092
[TBL] [Abstract][Full Text] [Related]
60. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
